Matfin Glenn
Global Medical and Scientific Affairs, Takeda America Holdings, One Takeda Parkway, Deerfield, IL 60015, USA.
Curr Diab Rep. 2008 Feb;8(1):31-6. doi: 10.1007/s11892-008-0007-0.
Metabolic syndrome refers to a clustering of established and emerging cardiovascular disease (CVD) risk factors within a single individual. The established risk factors--such as obesity, diabetes, dyslipidemia, hypertension--and other emerging risk factors are closely related to central obesity (especially intra-abdominal adiposity). Insulin resistance is also an important factor in this syndrome's etiology. However, despite the potential use of having all the CVD risk factors under an umbrella diagnosis of metabolic syndrome, debate continues about the very existence of the metabolic syndrome. Despite the controversies, many existing therapies and new drugs in development are targeting the metabolic syndrome. To date, no drugs are approved specifically for treating the metabolic syndrome. This article discusses some of the challenges in developing therapies for the metabolic syndrome.
代谢综合征是指在同一个体中聚集了一系列已确定的和新出现的心血管疾病（CVD）风险因素。已确定的风险因素，如肥胖、糖尿病、血脂异常、高血压，以及其他新出现的风险因素都与中心性肥胖（尤其是腹内肥胖）密切相关。胰岛素抵抗也是该综合征病因中的一个重要因素。然而，尽管代谢综合征这一总体诊断涵盖了所有心血管疾病风险因素可能有一定用处，但关于代谢综合征是否真的存在仍存在争议。尽管存在争议，但许多现有疗法和正在研发的新药都以代谢综合征为靶点。迄今为止，尚无专门批准用于治疗代谢综合征的药物。本文讨论了开发代谢综合征治疗方法所面临的一些挑战。
